{"id":"NCT03691844","sponsor":"Amzell","briefTitle":"AMZ001 for the Treatment of Knee Osteoarthritis Symptoms","officialTitle":"A Placebo-controlled, Double-blind, Randomized, Trial of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-10-04","primaryCompletion":"2019-07-09","completion":"2019-07-09","firstPosted":"2018-10-02","resultsPosted":"2020-10-06","lastUpdate":"2020-10-06"},"enrollment":444,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee"],"interventions":[{"type":"DRUG","name":"AMZ001","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Comparator","otherNames":["active comparator"]}],"arms":[{"label":"AMZ001 + Placebo","type":"EXPERIMENTAL"},{"label":"AMZ001","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.","primaryOutcome":{"measure":"WOMAC Pain Sub-score","timeFrame":"baseline, week 4","effectByArm":[{"arm":"AMZ001 BID","deltaMin":-26.49,"sd":null},{"arm":"AMZ001 + Placebo QD","deltaMin":-27.33,"sd":null},{"arm":"Placebo BID","deltaMin":-22.73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States","Czechia","Denmark"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":121},"commonTop":["Application Site erythema","Application site dryness","Application site pruritus","Nasopharyngitis","Headache"]}}